Androgen Receptor-CaMKK2 Axis in Prostate Cancer and Bone Microenvironment

dc.contributor.authorDadwal, Ushashi C.
dc.contributor.authorChang, Eric S.
dc.contributor.authorSankar, Uma
dc.contributor.departmentAnatomy and Cell Biology, School of Medicineen_US
dc.date.accessioned2019-05-28T14:08:28Z
dc.date.available2019-05-28T14:08:28Z
dc.date.issued2018-06-18
dc.description.abstractThe skeletal system is of paramount importance in advanced stage prostate cancer (PCa) as it is the preferred site of metastasis. Complex mechanisms are employed sequentially by PCa cells to home to and colonize the bone. Bone-resident PCa cells then recruit osteoblasts (OBs), osteoclasts (OCs), and macrophages within the niche into entities that promote cancer cell growth and survival. Since PCa is heavily reliant on androgens for growth and survival, androgen-deprivation therapy (ADT) is the standard of care for advanced disease. Although it significantly improves survival rates, ADT detrimentally affects bone health and significantly increases the risk of fractures. Moreover, whereas the majority patients with advanced PCa respond favorably to androgen deprivation, most experience a relapse of the disease to a hormone-refractory form within 1-2 years of ADT. The tumor adapts to surviving under low testosterone conditions by selecting for mutations in the androgen receptor (AR) that constitutively activate it. Thus, AR signaling remains active in PCa cells and aids in its survival under low levels of circulating androgens and additionally allows the cancer cells to manipulate the bone microenvironment to fuel its growth. Hence, AR and its downstream effectors are attractive targets for therapeutic interventions against PCa. Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2), was recently identified as a key downstream target of AR in coordinating PCa cell growth, survival, and migration. Additionally, this multifunctional serine/threonine protein kinase is a critical mediator of bone remodeling and macrophage function, thus emerging as an attractive therapeutic target downstream of AR in controlling metastatic PCa and preventing ADT-induced bone loss. Here, we discuss the role played by AR-CaMKK2 signaling axis in PCa survival, metabolism, cell growth, and migration as well as the cell-intrinsic roles of CaMKK2 in OBs, OCs, and macrophages within the bone microenvironment.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationDadwal, U. C., Chang, E. S., & Sankar, U. (2018). Androgen Receptor-CaMKK2 Axis in Prostate Cancer and Bone Microenvironment. Frontiers in endocrinology, 9, 335. doi:10.3389/fendo.2018.00335en_US
dc.identifier.urihttps://hdl.handle.net/1805/19487
dc.language.isoen_USen_US
dc.publisherFrontiers Mediaen_US
dc.relation.isversionof10.3389/fendo.2018.00335en_US
dc.relation.journalFrontiers in Endocrinologyen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.sourcePMCen_US
dc.subjectCAMKK2en_US
dc.subjectAndrogen-deprivation therapyen_US
dc.subjectBone–tumor microenvironmenten_US
dc.subjectCastrate-resistant prostate canceren_US
dc.subjectTreatment induced bone lossen_US
dc.titleAndrogen Receptor-CaMKK2 Axis in Prostate Cancer and Bone Microenvironmenten_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
fendo-09-00335.pdf
Size:
707.12 KB
Format:
Adobe Portable Document Format
Description:
Main article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: